Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07170189 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
NCT07170189 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 59 participants.
The verdict
NCT07170189, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
Study Summary
This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as single or multiple tablets) or HU6 300 mg twice daily (BID) (supplied as two 150 mg tablets) or HU6 150 mg drug substance in a capsule × 3 (450 mg total dose) QD or HU6 150 mg granulated blend in a capsule × 3 (450 mg total dose) QD.
Interventions
- DRUG HU6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07170189
The ClinicalTrials.gov registry entry for NCT07170189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HU6 is the first listed.
NCT07170189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07170189 about?
NCT07170189 is a clinical study titled "Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6". This is a five-part study being conducted to evaluate the safety, tolerability and pharmacokinetics of the HU6 tablet and capsule formulations at steady state in the fed and fasted state for HU6 450 mg once daily (QD) dose (as single or multiple tablets) or HU6 300 mg twice daily (BID) (supplied as ...
What is the current status of trial NCT07170189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2025-10-13. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT07170189?
The interventions under investigation include: HU6 (DRUG).
Who is sponsoring clinical trial NCT07170189?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.